CHARLOTTESVILLE, VA, April 2 /CNW/ - Biovista Inc. today announced that
BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant
positive results in the MOG-induced Experimental Allergic Encephalomyelitis
(EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned
in MS and is aimed at neuroprotection, was shown to have both efficacy in
reducing symptoms and no toxic effects in this well established model of MS.
"We are excited about these early results that confirm the predictive
capability of our repositioning platform technology and encourage us to
further develop this compound in a disease area where there is a significant
need for new therapies" said Aris Persidis, Ph.D., President of Biovista.
"What is also encouraging is that we reached this stage just 4 months after
deciding to work in MS. At the present time we are exploring all options
available to us, including the further co-development with a pharmaceutical
company and the licensing of the IP to a generics company" Dr. Persidis added.
About Biovista's BVA-101 trial in the MS EAE-MOG model
MS is a chronic inflammatory disease of the CNS with unknown etiology. It
is the most frequent non-traumatic disabling neurologic disease among young
adults, with 12,000 new diagnoses per year in the US alone, and over 2.5
million patients worldwide. In the animal proof of concept trial, BVA-101 was
compared to dexamethasone, a potent anti-inflammatory and immunosuppressive
drug that is efficient in accelerating the recovery from MS relapses but too
toxic for chronic use. BVA-101 induced a statistically significant reduction
of EAE severity, the magnitude of which was statistically similar to that
caused by dexamethasone.
About Biovista's repositioning pipeline and technology platform
Biovista applies high-throughput discovery efforts to finding solutions
for commercially relevant unmet medical needs. Biovista's proprietary
repositioning technology allows the company's experts to perform
mechanism-of-action based analyses and systematically assess clinical outcomes
in any therapeutic area of interest, at relatively low cost and very short
time spans. The company is presently using this platform to develop its own
pipeline of repositioned drugs in areas such as CNS, cardiovascular disease,
oncology and auto-immune diseases and is expecting to make further
announcements in Q3 '09.
For further information:
For further information: Dr. Aris Persidis, Biovista Inc., (434)
242-6514, firstname.lastname@example.org; For a non-confidential information pack on
BVA-101 contact Biovista at email@example.com